Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02880007
PHASE2

Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer

Sponsor: Institut de Cancérologie de Lorraine

View on ClinicalTrials.gov

Summary

This prospective phase II trial study aims to optimize the increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy in treating patients with locally advanced cervical cancer.

Official title: A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2011-06-06

Completion Date

2019-07-01

Last Updated

2026-09-01

Healthy Volunteers

No

Interventions

RADIATION

External Beam Radiation Therapy

45 Gy pelvis / 25 fr

RADIATION

PDR Brachytherapy

1 puls/hour ; 12 Gy / day

DRUG

Cisplatin

increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy

Locations (9)

CHU de Besançon

Besançon, France

Institut Bergonié

Bordeaux, France

Centre Georges-François Leclerc

Dijon, France

Centre Léon Bérard

Lyon, France

Centre Val d'Aurelle

Montpellier, France

Centre Paul Strauss

Strasbourg, France

Centre Claudius Regaud

Toulouse, France

CHRU Tours - Hôpital Bretonneau

Tours, France

Institut de Cancérologie de Lorraine

Vandœuvre-lès-Nancy, France